Expergen Drug Development

Expergen Drug Development GmbH is an Austrian biotechnology company based in Vienna, specializing in the development of pharmaceutical formulations and drug delivery systems for oncology and orphan diseases. The company's primary focus has been on the repurposing and reformulation of existing compounds, notably miltefosine and naloxone, for the treatment of cutaneous T-cell lymphoma (CTCL). Expergen holds orphan drug designations in the European Union and the United States for miltefosine in CTCL and has developed proprietary liquid pharmaceutical forms of alkylphosphocholines. The company has a history of strategic settlements and intellectual property management, including agreements with Thallion Pharmaceuticals regarding oncology candidates.